Virtual screening based on molecular docking of lysosomotropic compounds as therapeutic agents for COVID-19

Authors

  • João Batista de Andrade Neto Federal University of Ceará http://orcid.org/0000-0002-3180-3012
  • Emanuelle Machado Marinho Federal University of Ceará
  • Cecília Rocha da Silva Federal University of Ceará,
  • Lívia Gurgel do Amaral Valente Sá Christus University Center (UNICHRISTUS) http://orcid.org/0000-0002-0619-2782
  • Vitória Pessoa de Farias Cabral Federal University of Ceará http://orcid.org/0000-0002-6408-7200
  • Thiago Mesquita Cândido Federal University of Ceará
  • Wildson Max Barbosa da Silva Christus University Center (UNICHRISTUS)
  • Letícia Bernardo Barbosa Christus University Center (UNICHRISTUS) http://orcid.org/0000-0003-0276-711X
  • Bruno Coelho Cavalcanti Federal University of Ceará, Fortaleza
  • Pedro de Lima Neto Department of Analytical Chemistry and Physical Chemistry, Group of Theoretical Chemistry
  • Emmanuel Silva Marinho State University of Ceará http://orcid.org/0000-0002-4774-8775
  • Akenaton Onassis Cardoso Viana Gomes Federal University of Ceará
  • Hélio Vitoriano Nobre Júnior Federal University of Ceará

DOI:

https://doi.org/10.12662/2317-3076jhbs.v10i1.4238.p1-12.2022

Keywords:

Lysosomotropic agents, SARS-CoV, Molecular Docking

Abstract

INTRODUCTION: COVID-19 has quickly become one of the main pathogens of the human respiratory tract and poses a great threat to public health. The high number of cases has caused the World Health Organization to declare a global state of emergency. In addition, due to the limited number of therapeutic strategies, high levels of mortality have been observed in several regions of the world. Within this context, repositioning of drugs based on lysosomotropic and endolysosomal pH modulating effects can provide additional options for therapy and prevention of the new disease. METHODS: Molecular docking analyses of these lysosomotropic agents were performed, namely of fluoxetine, imipramine, chloroquine, verapamil, tamoxifen, amitriptyline and chlorpromazine against important targets for the pathogenesis of SARS-CoV-2. RESULTS: The results revealed that the inhibitors bind to distinct regions of Mpro COVID-19, with variations in RMSD values from 1.325 to 1.962 Å and a binding free energy of -5.2 to -4.3 kcal/mol. Furthermore, the analysis of the second target showed that all inhibitors bonded at the same site as the enzyme and the interaction resulted in an RMSD variation of 0.735 to 1.562 Å and binding free energy ranging from -6.0 to -8.7 kcal/mol. CONCLUSION: Therefore, this study allows proposing the use of these lysosomotropic compounds. However, these computer simulations are just an initial step toward conceiving new projects for the development of antiviral molecules.

 

Keywords: COVID-19; Inhibitors; lysossomotropics; molecular docking

Downloads

Download data is not yet available.

Downloads

Published

2022-06-30

How to Cite

1.
de Andrade Neto JB, Marinho EM, da Silva CR, Valente Sá LG do A, Cabral VP de F, Cândido TM, et al. Virtual screening based on molecular docking of lysosomotropic compounds as therapeutic agents for COVID-19. J Health Biol Sci. [Internet]. 2022 Jun. 30 [cited 2024 Dec. 23];10(1):1-12. Available from: https://unichristus.emnuvens.com.br/jhbs/article/view/4238

Issue

Vol. 10 No. 1 (2022): Journal of Health and Biological Sciences

Section

Original articles

License

Authors who publish with this journal agree to the following terms:


a) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).


Declaration

Transfer of Copyright


The author hereby declare that the article entitled "TITLE OF THE ARTICLE" approved for publication in the Journal of Health & Biological Sciences is an original work that has not been published or is being considered for publication elsewhere, that is in print or electronic.
The author's manuscript quoted above also states (m):

  1. I certify that I have participated sufficiently in the work to take public responsibility for the content.
  2. I declare that the use of any trademark or copyright in the manuscript has been credited to its owner or permission to use the name was given, if necessary.
  3. I declare that I agree that the copyright for the article referenced above will become the exclusive property of the Journal of Health & Biological Sciences - JHBS, any form of reproduction, in whole or in part, in any form or means of disclosure, printed or electronic, without the prior authorization is required, and, if obtained, I include my thanks to the Journal of Health & Biological Sciences - JHBS.
  4. The original submission to the Journal of Health and Biological Sciences (JHBS) imply transfer by authors, printed and digital publishing rights.

Note: All persons listed as authors must sign this statement and signed statements will not be accepted by others.
The original statement shall be signed, dated and sent to the address below or by email:
JOURNAL OF BIOLOGICAL SCIENCES & HEALTH
Councilman Paul Street Mamede, 130 - 5th floor - Neighborhood: Coco.
Fortaleza - CE
CEP 60192-350
Phone: (85) 3265-8109, Ext: 8109
e-mail: @ secretaria.jhbs fchristus.edu.br